SPRY Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -2.49%, SMA50 -10.39%, SMA200 -23.33%). The stock’s 14-day RSI is 44.24 (neutral), while the ATR of 0.56 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.58% below its high and over 40.24% above its low. Average 10-day trading volume of 1.29 million shares is below the 3-month average of 2.02 million, indicating normal recent market interest.

The latest quarter delivered EPS of -$0.63. The next quarter is forecast at -$0.43. Next year's EPS is expected at -$17.49. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $24.00. The high target offers 530.25% upside. The low target suggests 404.2% downside. The mean target is $27.00. This offers 467.23% upside. ARS Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by 31.89%. The prior quarter beat by 15.09%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 14, 2025.

ARS Pharmaceuticals, Inc. has 99.30 million shares outstanding. The public float is 48.43 million shares, elevated short interest at 32.94% of float. This equals 22.67 million shares. The short ratio is 11.35 days. Institutional investors hold 109.86% of the float. Insiders own 16.18%. RA CAPITAL MANAGEMENT, L.P. holds 9.96 million shares, Flynn James E has 4.89 million shares and Tanimoto Sarina has 1.25 million shares. Over the past six months, insider transactions show net selling. They sold 28.36 thousand shares across 2 transactions.

ARS Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.71. This means the shares are trading below this model’s fair value.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) closed at $4.50 USD, losing -$0.26 (-5.46%) from the previous close of $4.76. The stock is currently within 5% of its 52-week low $4.46 and $13.15. With a market capitalization of about $446.86 million, ARS Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.88). Key stats such as the average daily volume over the past year has been around 2.02 million shares, in line with its 52-week average. Headquartered in San Diego, CA, ARS Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Donn Casale, the company employs approximately 195 people and listed since December 04, 2020. ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology.

ARS Pharmaceuticals, Inc. trades at a P/E ratio of -2.11, slightly below the S&P 500 average, with a price-to-sales ratio of 3.9 and a price-to-book ratio of 36.43 reflecting a rich premium to book value. The P/FCF stands at -2.32, also above market averages. Compared to sector medians, ARS Pharmaceuticals, Inc. P/S is broadly in line with the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that ARS Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.31%, with price expected at $4.87 by September 25, 2026, within a range of $4.45 to $5.31 3-Month Outlook: Projected fall of -42.23%, reaching $2.75 by December 10, 2026, with a range of $2.43 to $3.03. 1-Year Outlook: Projected loss of -62.82%, with price at $1.77 by September 10, 2027, within a range of $0.00 to $0.00.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares are down -10.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ARS Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.11. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $21.95, suggesting 361.13% upside. Our AI forecast model points to short-term strength (2.31% over two weeks), a medium-term fall (-42.23% over three months), and a longer-term loss (-62.82% over one year), with expected trading ranges indicating moderate volatility.